Developer docs
API playgroundTry for free, no card

Search company profiles

Biomedican

Full company profile

uuid00042ik

Namestring
Biomedican
Legal namestring
Biomedican Inc.
Websiteurl
biomedican.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFremont, United States
HQ citystring
Fremont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosynthetic cannabinoid production, yeast fermentation platform, pharmaceutical-grade compounds, rare cannabinoid biosynthesis, natural astaxanthin production
Industry1 code
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biosynthetic Pharmaceutical Ingredients
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biosynthesized Rare Cannabinoids Sales
TypeOne Time License
Description

Revenue from selling pharmaceutical-grade biosynthesized rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) to pharmaceutical, nutraceutical, cosmetics, food and beverage, and pet care companies. Products offered at 70-90% lower cost than conventional methods with 99% purity levels.

biomedican.com
2Astaxanthin Product Sales
TypeOne Time License
Description

Revenue from biosynthesized astaxanthin production for human and animal consumption. Natural astaxanthin produced at fraction of cost compared to algae extraction ($5000/kilo) or chemical synthesis, with better bioavailability and bioidentical molecular structure.

biomedican.com
3Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Potential licensing of proprietary biosynthesis platform technology and patent portfolio to other companies in the cannabinoid and biotechnology space. Joint venture with Full Spectrum Biosciences for pilot production programs.

biomedican.com
4IPO/Public Offering
TypeOne Time License
Description

Company has laid out plans to go public in first half of 2021 according to Reuters coverage. Stock listing planned for capital raise and public trading.

biomedican.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Production costs 70-90% below market wholesale prices
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Company produces rare cannabinoids at production costs 70-90% lower than current wholesale prices. For example, CBG wholesale is $20/gram, and Biomedican can produce for under $1/gram. THCV and THCVA produced at over 90% less than current wholesale prices. CBG/CBGA produced 75-90% less expensive than current wholesale prices. Production requires only sugar, water, and YL yeast.

biomedican.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Bio-Kai
Description

A brand that produces astaxanthin, a carotenoid with various health benefits.

biomedican.com
Core offering1 text field

Biomedican produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) and biosynthesized astaxanthin through a proprietary Yarrowia lipolytica yeast fermentation platform. Production costs are 70–90% lower than conventional plant extraction or chemical synthesis methods, with 99% purity and bioidentical molecular structure. Products are sold in bulk to enterprise buyers in pharmaceutical, nutraceutical, cosmetics, food & beverage, and pet care industries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 99% pharmaceutical-grade purity achieved
+4 more records
Product overview1 text field

Biomedican is a biotech company that produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids using a proprietary organic biosynthesis platform based on yeast fermentation (Yarrowia Lipolytica). The company's core product portfolio consists of CBG/CBGA, CBN/CBNA, THCA, and THCV/THCVA - all biosynthesized at 70-90% lower cost than conventional methods. The company has diversified into Astaxanthin production, leveraging the same biosynthesis platform to target additional high-value compounds beyond cannabinoids.

Product and service5 records
1CBG/CBGA
CategoryPharmaceutical-grade Cannabinoid Ingredients
Description

Cannabigerol (CBG) and Cannabigerolic acid (CBGA) produced at pharmaceutical-grade, 100% organic, non-GMO purity via proprietary yeast fermentation. Target applications include anti-inflammatory, pain relief, glaucoma treatment, and inflammatory bowel disease. Sold in bulk to enterprise buyers in pharma, nutraceuticals, cosmetics, and pet care.

2CBN/CBNA
CategoryPharmaceutical-grade Cannabinoid Ingredients
Description

Cannabinol (CBN) and Cannabinolic acid (CBNA) produced at pharmaceutical-grade via biosynthesis, noted for sleep aid properties and relaxing effects without heavy psychological impact. Sold to enterprise buyers for nutraceutical and therapeutic applications.

3THCA
CategoryPharmaceutical-grade Cannabinoid Ingredients
Description

Tetrahydrocannabinolic acid (THCA), a non-psychoactive rare cannabinoid biosynthesized using the proprietary Y. lipolytica platform. Documented anti-tumor effects via reduced angiogenesis and activation of apoptotic pathways. Sold as a pharmaceutical-grade API to enterprise buyers.

4THCV/THCVA
CategoryPharmaceutical-grade Cannabinoid Ingredients
Description

Tetrahydrocannabivarin (THCV) and Tetrahydrocannabivarinic acid (THCVA) at pharmaceutical grade with neuroprotective and appetite reduction effects. Suitable for weight management products and Parkinson's disease therapeutics; sold to food & beverage, nutraceutical, and pharmaceutical buyers.

5Astaxanthin
CategoryBiosynthetic High-Value Compounds
Description

Biosynthesized natural astaxanthin, marketed as the world's strongest natural antioxidant, produced at 90% lower cost than chemical synthesis and yielding 70% astaxanthin, 17% beta-carotene, and 10% canthaxanthin composition. Used in cosmetics, wellness supplements, dietary supplements, and pet care applications with improved bioavailability.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Astaxanthin Market Entry
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-12-02
Description

Biomedican entered the astaxanthin market to diversify products outside of cannabinoids. The biosynthesis platform targets any high-value compound and significantly disrupts current technologies. Astaxanthin production via bioengineered yeast planned to be spun off into a separate subsidiary.

biomedican.com
2Full Spectrum Biosciences (Agritek Holdings)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-10
Description

Full Spectrum Biosciences Inc., a wholly-owned subsidiary of Agritek Holdings Inc. (AGTK), and Biomedican have executed a Letter of Intent and completed a joint venture agreement for the first test pilot program using Biomedican's patented biosynthetic methods using yeast fermentation. The partnership aims to ensure efficient production of high-quality cannabinoid profiles and compounds. Full Spectrum provides IP, formulation, and white label services for popular hemp brands including RehabRx and Hemp Pops.

biomedican.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Cronophyta
TypeEmerging player
Description

Emerging algal/microbial biotechnology producers of high-value compounds such as astaxanthin compete with Biomedican's astaxanthin subsidiary Bio-Kai on the alternative natural-antioxidant supply story.

TypeDirect peer
Description

CB Therapeutics uses yeast fermentation to produce a portfolio of rare cannabinoids and psilocybin-related compounds, directly overlapping Biomedican's product roadmap and customer base.

TypeDirect peer
Description

Willow Biosciences (formerly Willow Inc.) develops yeast-based biosynthetic platforms for the production of rare cannabinoids (CBG, CBD, THC variants), competing head-to-head with Biomedican for pharmaceutical-grade cannabinoid API supply.

TypeBroad incumbent
Description

Cronos Group has a multi-year strategic partnership with Ginkgo Bioworks to develop and commercialize cultured rare cannabinoids. As a top-tier cannabis incumbent, it is a likely off-take customer or competitor depending on Ginkgo's commercial path.

TypeBroad incumbent
Description

Amyris operates large-scale fermentation for specialty ingredients (squalane, beta-carotene, etc.) and has publicly explored cannabinoid production. It is a broad fermentation incumbent against which Biomedican must differentiate on strain efficiency.

TypeDirect peer
Description

Hyasynth Biologicals is a Canadian biotech producing rare cannabinoids via engineered yeast fermentation, with a comparable IP-driven platform approach and pharmaceutical target customer base as Biomedican.

TypeDirect peer
Description

Antheia uses synthetic biology and yeast fermentation to produce opioid and other alkaloid APIs, and has expanded into cannabinoid manufacture. It is a direct biosynthetic-API competitor serving similar pharmaceutical customers.

TypeDirect peer
Description

Demetrix (backed by Cavallo Ventures, T. Marzetti) ferments rare cannabinoids via engineered yeast at commercial scale, directly competing for the same pharmaceutical and nutraceutical API opportunities.

TypeBroad incumbent
Description

Ginkgo is the largest synthetic biology platform company and partnered with Cronos Group to biosynthesize cannabinoids. While not a cannabinoid pure-play, its scale, foundry model, and existing Cronos relationship make it the dominant incumbent in the space.

TypeRegional player
Description

InMed is a Canadian clinical-stage pharmaceutical company developing rare cannabinoid-based drug candidates (e.g., INM-755 for epidermolysis bullosa). It is a downstream therapeutic buyer of cannabinoid APIs and adjacent rather than a direct biosynthesis competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biomedican

Biosynthetic Pharmaceutical Ingredientsbiomedican.com

Biomedican firmographics

Firmographics
Name
Biomedican
Legal name
Biomedican Inc.
Website
https://biomedican.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Biomedican industry classification

Industry
Product category
Biosynthetic Pharmaceutical Ingredients
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Biosynthetic cannabinoid production
  • Yeast fermentation platform
  • Pharmaceutical-grade compounds
  • Rare cannabinoid biosynthesis
  • Natural astaxanthin production

Where Biomedican is headquartered

Location

Headquarters

HQ city
Fremont
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biomedican business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Biosynthesized Rare Cannabinoids Sales: Revenue from selling pharmaceutical-grade biosynthesized rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) to pharmaceutical, nutraceutical, cosmetics, food and beverage, and pet care companies. Products offered at 70-90% lower cost than conventional methods with 99% purity levels.
  2. Astaxanthin Product Sales: Revenue from biosynthesized astaxanthin production for human and animal consumption. Natural astaxanthin produced at fraction of cost compared to algae extraction ($5000/kilo) or chemical synthesis, with better bioavailability and bioidentical molecular structure.
  3. Licensing and Partnership Revenue: Potential licensing of proprietary biosynthesis platform technology and patent portfolio to other companies in the cannabinoid and biotechnology space. Joint venture with Full Spectrum Biosciences for pilot production programs.
  4. IPO/Public Offering: Company has laid out plans to go public in first half of 2021 according to Reuters coverage. Stock listing planned for capital raise and public trading.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goProduction costs 70-90% below market wholesale prices

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

Biomedican product offering

Product offering

Core offering

Biomedican produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) and biosynthesized astaxanthin through a proprietary Yarrowia lipolytica yeast fermentation platform. Production costs are 70–90% lower than conventional plant extraction or chemical synthesis methods, with 99% purity and bioidentical molecular structure. Products are sold in bulk to enterprise buyers in pharmaceutical, nutraceutical, cosmetics, food & beverage, and pet care industries.

Product overview

Biomedican is a biotech company that produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids using a proprietary organic biosynthesis platform based on yeast fermentation (Yarrowia Lipolytica). The company's core product portfolio consists of CBG/CBGA, CBN/CBNA, THCA, and THCV/THCVA - all biosynthesized at 70-90% lower cost than conventional methods. The company has diversified into Astaxanthin production, leveraging the same biosynthesis platform to target additional high-value compounds beyond cannabinoids.

Differentiator

Problem solved

Functional benefit

Brands

  • Bio-Kai: A brand that produces astaxanthin, a carotenoid with various health benefits.

Products and services

  • CBG/CBGA Cannabigerol (CBG) and Cannabigerolic acid (CBGA) produced at pharmaceutical-grade, 100% organic, non-GMO purity via proprietary yeast fermentation. Target applications include anti-inflammatory, pain relief, glaucoma treatment, and inflammatory bowel disease. Sold in bulk to enterprise buyers in pharma, nutraceuticals, cosmetics, and pet care.
  • CBN/CBNA Cannabinol (CBN) and Cannabinolic acid (CBNA) produced at pharmaceutical-grade via biosynthesis, noted for sleep aid properties and relaxing effects without heavy psychological impact. Sold to enterprise buyers for nutraceutical and therapeutic applications.
  • THCA Tetrahydrocannabinolic acid (THCA), a non-psychoactive rare cannabinoid biosynthesized using the proprietary Y. lipolytica platform. Documented anti-tumor effects via reduced angiogenesis and activation of apoptotic pathways. Sold as a pharmaceutical-grade API to enterprise buyers.
  • THCV/THCVA Tetrahydrocannabivarin (THCV) and Tetrahydrocannabivarinic acid (THCVA) at pharmaceutical grade with neuroprotective and appetite reduction effects. Suitable for weight management products and Parkinson's disease therapeutics; sold to food & beverage, nutraceutical, and pharmaceutical buyers.
  • Astaxanthin Biosynthesized natural astaxanthin, marketed as the world's strongest natural antioxidant, produced at 90% lower cost than chemical synthesis and yielding 70% astaxanthin, 17% beta-carotene, and 10% canthaxanthin composition. Used in cosmetics, wellness supplements, dietary supplements, and pet care applications with improved bioavailability.

Quantifiable outcome

  • 99% pharmaceutical-grade purity achieved
  • +4 more outcomes

Companies that use Biomedican

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Biomedican technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Biomedican partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Astaxanthin Market EntryminorStrategic or Co-development Partner · 2 December 2020Biomedican entered the astaxanthin market to diversify products outside of cannabinoids. The biosynthesis platform targets any high-value compound and significantly disrupts current technologies. Astaxanthin production via bioengineered yeast planned to be spun off into a separate subsidiary.
  • Full Spectrum Biosciences (Agritek Holdings)coreStrategic or Co-development Partner · 10 November 2020Full Spectrum Biosciences Inc., a wholly-owned subsidiary of Agritek Holdings Inc. (AGTK), and Biomedican have executed a Letter of Intent and completed a joint venture agreement for the first test pilot program using Biomedican's patented biosynthetic methods using yeast fermentation. The partnership aims to ensure efficient production of high-quality cannabinoid profiles and compounds. Full Spectrum provides IP, formulation, and white label services for popular hemp brands including RehabRx and Hemp Pops.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Biomedican competitors and assessment

Company assessment

Emerging players

  • Cronophyta: Emerging algal/microbial biotechnology producers of high-value compounds such as astaxanthin compete with Biomedican's astaxanthin subsidiary Bio-Kai on the alternative natural-antioxidant supply story.

Direct peers

  • CB Therapeutics: CB Therapeutics uses yeast fermentation to produce a portfolio of rare cannabinoids and psilocybin-related compounds, directly overlapping Biomedican's product roadmap and customer base.
  • Willow Biosciences: Willow Biosciences (formerly Willow Inc.) develops yeast-based biosynthetic platforms for the production of rare cannabinoids (CBG, CBD, THC variants), competing head-to-head with Biomedican for pharmaceutical-grade cannabinoid API supply.
  • Hyasynth Biologicals: Hyasynth Biologicals is a Canadian biotech producing rare cannabinoids via engineered yeast fermentation, with a comparable IP-driven platform approach and pharmaceutical target customer base as Biomedican.
  • Antheia: Antheia uses synthetic biology and yeast fermentation to produce opioid and other alkaloid APIs, and has expanded into cannabinoid manufacture. It is a direct biosynthetic-API competitor serving similar pharmaceutical customers.
  • Demetrix: Demetrix (backed by Cavallo Ventures, T. Marzetti) ferments rare cannabinoids via engineered yeast at commercial scale, directly competing for the same pharmaceutical and nutraceutical API opportunities.

Broad incumbents

  • Cronos Group: Cronos Group has a multi-year strategic partnership with Ginkgo Bioworks to develop and commercialize cultured rare cannabinoids. As a top-tier cannabis incumbent, it is a likely off-take customer or competitor depending on Ginkgo's commercial path.
  • Amyris: Amyris operates large-scale fermentation for specialty ingredients (squalane, beta-carotene, etc.) and has publicly explored cannabinoid production. It is a broad fermentation incumbent against which Biomedican must differentiate on strain efficiency.
  • Ginkgo Bioworks: Ginkgo is the largest synthetic biology platform company and partnered with Cronos Group to biosynthesize cannabinoids. While not a cannabinoid pure-play, its scale, foundry model, and existing Cronos relationship make it the dominant incumbent in the space.

Regional players

  • InMed Pharmaceuticals: InMed is a Canadian clinical-stage pharmaceutical company developing rare cannabinoid-based drug candidates (e.g., INM-755 for epidermolysis bullosa). It is a downstream therapeutic buyer of cannabinoid APIs and adjacent rather than a direct biosynthesis competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Biomedican social profiles

Digital presence

Biomedican financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biomedican leadership team

Management profile

Number of profiles

Profiles6 records

Biomedican funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biomedican M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomedican

What does Biomedican do?

Biomedican produces pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids (CBG, CBGA, CBN, CBNA, THCA, THCV, THCVA) and biosynthesized astaxanthin through a proprietary Yarrowia lipolytica yeast fermentation platform. Production costs are 70–90% lower than conventional plant extraction or chemical synthesis methods, with 99% purity and bioidentical molecular structure. Products are sold in bulk to enterprise buyers in pharmaceutical, nutraceutical, cosmetics, food & beverage, and pet care industries.

Is Biomedican a public or private company?

Biomedican is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biomedican founded?

Biomedican was founded in 2017. It employs 11 to 50 people.

Where is Biomedican based?

Biomedican is headquartered in Fremont, United States, in the North America region.

How does Biomedican make money?

Four revenue lines are on record. Biosynthesized Rare Cannabinoids Sales are the primary driver. The others are astaxanthin Product Sales, licensing and Partnership Revenue and IPO/Public Offering.

Who are Biomedican's main competitors?

Cronophyta is listed as an emerging player. Direct peers are CB Therapeutics, Willow Biosciences, Hyasynth Biologicals, Antheia and Demetrix. Broad incumbents are Cronos Group, Amyris and Ginkgo Bioworks. InMed Pharmaceuticals is listed as a regional player.

Does Biomedican have an API?

No public API is recorded for Biomedican.

What industry is Biomedican in?

Biomedican's product category is Biosynthetic Pharmaceutical Ingredients. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaThe Bio Revolution of Medical Cannabinoid TherapeuticsThis analysis piece discusses the emerging field of biosynthesized cannabinoids, describing how companies are engineering organisms like yeast and bacteria to produce cannabinoids through fermentation, potentially offering higher quality and lower cost production than traditional cannabis cultivation. The article identifies several companies competing in this space—Demetrix, Cronos, CREO, Willow Bio, and Biomedican—while noting that Biomedican currently leads with 5% dry cell mass yields and production costs under $1 per gram. Aurora Cannabis and Biomedican are identified as the only two companies holding patents for Olivetolic Acid, a critical component in cannabinoid biosynthesis.PR NewswireBiomedican Receives Approval Notification From the U.S. Patent Office on Its 1st PatentBiomedican received approval notification from the U.S. Patent Office for its first patent, which covers the use of Yarrowia Lipolytica yeast to produce cannabinoids. This milestone allows the company to achieve higher yields and lower production costs compared to competitors using other biological systems. The company expects this technology to provide a significant competitive advantage in the growing biosynthesized cannabinoid market.ObserverCannabinoids Are the Next Big Thing in the Pot Industry, But Who Can Mass-Produce It?The startup Demetrix is preparing to manufacture large quantities of cannabigerol (CBG) in Berkeley, California, with products expected by the end of the year. Biomedican, another California-based startup, is also focused on rare cannabinoids and projects the industry may be worth $25 billion by 2025. Both companies utilize engineered yeast to produce these cannabinoids on a commercial scale, addressing a rising consumer interest in niche marijuana products.PR NewswireBioMedican Discovers New Class of Cannabinoids; Sesqui CBGBioMedican has discovered and filed a patent for a new class of rare Cannabinoids called Sesqui-Cannabinoids, which they can now biosynthesize, with the company expecting to expand production to include Sesqui-CBD, Sesqui-CBN, Sesqui-THCV, and Sesqui-THCA within six months. The company claims this discovery represents a potential breakthrough in rare Cannabinoid production, reducing costs by 70-90% while producing pharmaceutical-grade compounds with 0.0% THC. BioMedican is actively seeking research partners, including university collaborations, to investigate the health benefits of this new class of Cannabinoids.PR NewswireBIOMEDICAN Enters the Global Astaxanthin Market Through Its Patented Biosynthesis PlatformBIOMEDICAN, a San Francisco-based biotech company, has entered the global Astaxanthin market using its patented biosynthesis platform, diversifying beyond its existing cannabinoid operations. The company's production process creates non-GMO, organic Astaxanthin at 90% less cost than chemical synthesis, targeting the animal feed, fish feed, and human consumption segments of a market projected to grow from $1 billion in 2019 to $3.3 billion by 2027. The company reports significant buyer interest and is conducting bioavailability tests with two of the world's largest Astaxanthin buyers, with expectations of tens of millions of dollars in orders next year.NewswireBIOMEDICAN Announces Organic Biosynthesis of Rare Cannabinoid THCV/THCVABIOMEDICAN announced organic biosynthesis of rare cannabinoid THCV/THCVA, producing pharmaceutical-grade, non-GMO compound at over 90% lower cost than wholesale. The biosynthetic market is projected to reach $10 billion by 2025, with THCV/THCVA expected to hold a top three market share.PR NewswireBIOMEDICAN Announces Organic Biosynthesis of Rare Cannabinoid THCV/THCVABIOMEDICAN, a San Francisco-based biotech company, has successfully biosynthesized the rare cannabinoid THCV/THCVA using proprietary yeast-based methods, producing a pharmaceutical-grade, 100% organic, non-GMO product that is bioidentical to naturally occurring molecules. The company claims production costs are over 90% less than current wholesale prices, positioning it to serve pharmaceutical, nutraceuticals, CBD, health food, and cosmetics industries. The biosynthetic cannabinoid market is projected to reach $10 billion by 2025, with THCV/THCVA expected to become one of the top three cannabinoids by market share, and BIOMEDICAN states it is in discussions with pharmaceutical companies regarding clinical trials.PR NewswireBIOMEDICAN Announces Successful Biosynthesis of CBG/CBGA and Large-Scale ProductionBIOMEDICAN, a biotech company based in Fremont, California, has successfully biosynthesized the rare cannabinoid CBG/CBGA and plans to establish large-scale production. The pharmaceutical-grade product is said to be significantly cheaper than current wholesale prices and suitable for various channels, with production expected to start in late 2021.YahooIs The Cannabis Market Ready For Lab-Grown Cannabinoids?BiomediCan Inc. is utilizing genetically modified yeast to commercially produce rare cannabinoids like CBG and CBN, offering a plant-free alternative to traditional cultivation methods. This biosynthesis approach yields pharmaceutical-grade products that are claimed to be organic and GMO-free, targeting a market with growing therapeutic interest in minor cannabinoids.